{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:41Z","timestamp":1783977221974,"version":"3.55.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":232,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim was to evaluate retention rates for secukinumab in patients with active PsA or radiographic axial spondyloarthritis (r-axSpA) treated in routine UK clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SERENA (CAIN457A3403) is an ongoing, non-interventional, international study of patients with moderate-to-severe chronic plaque psoriasis, active PsA or active r-axSpA, who had received secukinumab for \u226516\u2009weeks before enrolment. The primary objective of this interim analysis was to assess treatment retention rates in patients with PsA or r-axSpA who were enrolled and followed for \u22652\u2009years at centres in the UK. The safety analysis set includes all patients who received at least one dose of secukinumab. The target population set includes all patients who fulfilled the patient selection criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The safety set comprised 189 patients (PsA, n\u2009=\u200981; r-axSpA, n\u2009=\u2009108), and the target population set comprised 183 patients (PsA, n\u2009=\u200978; r-axSpA, n\u2009=\u2009105). In the safety set, 107 patients (45 of 81 with PsA and 62 of 108 with r-axSpA) had previously received a biologic agent. Retention rates were similar between patients with PsA and r-axSpA after 1\u2009year (PsA 91.0%, 95% CI: 84.0, 98.0; r-axSpA 89.2%, 95% CI: 82.7, 95.7) and 2\u2009years (PsA 77.6%, 95% CI: 67.6, 87.7; r-axSpA 76.2%, 95% CI: 67.4, 85.0) of observation. Overall, 17.5% of patients (33 of 189) experienced at least one treatment-related adverse event, and 12.7% of patients (24 of 189) discontinued secukinumab because of adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This analysis of real-world data from the UK demonstrates high retention rates for secukinumab over 2\u2009years in patients with PsA or r-axSpA, with a favourable safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkad055","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T19:06:24Z","timestamp":1692644784000},"source":"Crossref","is-referenced-by-count":7,"title":["Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-9176","authenticated-orcid":false,"given":"Karl","family":"Gaffney","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Norfolk and Norwich University Hospitals, NHS Foundation Trust , Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gullick","sequence":"additional","affiliation":[{"name":"University Hospital Coventry & Warwickshire, Warwick Medical School, University of Warwick , Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"MacKay","sequence":"additional","affiliation":[{"name":"Rheumatology, Torbay and South Devon NHS Foundation Trust , Torquay, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Patel","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust , Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9720-0396","authenticated-orcid":false,"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Diseases, Royal United Hospitals , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sheeran","sequence":"additional","affiliation":[{"name":"University of Wolverhampton, Royal Wolverhampton NHS Trust , Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Hemmings","sequence":"additional","affiliation":[{"name":"Immunology, Novartis Pharmaceuticals UK Ltd , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Pamies","sequence":"additional","affiliation":[{"name":"Immunology, Novartis Pharmaceuticals UK Ltd , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2023090107271589500_rkad055-B1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2023090107271589500_rkad055-B2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2023090107271589500_rkad055-B3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.23910","article-title":"Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: results from a cross-sectional study","volume":"72","author":"Fern\u00e1ndez-Carballido","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090107271589500_rkad055-B4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.191117","article-title":"Disease characteristics, quality of life, and work productivity by enthesitis site: real-world data from the US Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"48","author":"Mease","year":"2021","journal-title":"J Rheumatol"},{"key":"2023090107271589500_rkad055-B5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2023090107271589500_rkad055-B6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","article-title":"Prevalence and treatment patterns of psoriatic arthritis in the UK","volume":"52","author":"Ogdie","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2023090107271589500_rkad055-B7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737167.2014.957679","article-title":"Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review","volume":"14","author":"Kotsis","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2023090107271589500_rkad055-B8","doi-asserted-by":"crossref","first-page":"e001206","DOI":"10.1136\/rmdopen-2020-001206","article-title":"Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis","volume":"6","author":"Derakhshan","year":"2020","journal-title":"RMD Open"},{"key":"2023090107271589500_rkad055-B9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12891-015-0853-2","article-title":"The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study","volume":"16","author":"Hamilton","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2023090107271589500_rkad055-B10","doi-asserted-by":"crossref","first-page":"8659302","DOI":"10.1155\/2019\/8659302","article-title":"Implication of IL-17 in bone loss and structural damage in inflammatory rheumatic diseases","volume":"2019","author":"Le Goff","year":"2019","journal-title":"Mediators Inflamm"},{"key":"2023090107271589500_rkad055-B11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023090107271589500_rkad055-B12","volume-title":"Cosentyx summary of product characteristics","year":"2019"},{"key":"2023090107271589500_rkad055-B13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023090107271589500_rkad055-B14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"2023090107271589500_rkad055-B15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"2023090107271589500_rkad055-B16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2023090107271589500_rkad055-B17","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2023090107271589500_rkad055-B18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2023090107271589500_rkad055-B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023090107271589500_rkad055-B20","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"2023090107271589500_rkad055-B21","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","article-title":"5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial","volume":"2","author":"Marzo-Ortega","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2023090107271589500_rkad055-B22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.11102","article-title":"Secukinumab 150\/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study","volume":"2","author":"Pavelka","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2023090107271589500_rkad055-B23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023090107271589500_rkad055-B24","first-page":"890","article-title":"FRI0406 AQUILA study in Germany \u2013 real world data on secukinumab\u2019s effectiveness in ankylosing spondylitis patients \u2013 results from an interim analysis","volume":"78(Suppl 2)","author":"Kiltz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023090107271589500_rkad055-B25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","article-title":"One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study","volume":"20","author":"Chimenti","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2023090107271589500_rkad055-B26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjd.18981","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023090107271589500_rkad055-B27","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/rheumatology\/keaa825","article-title":"Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis","volume":"60","author":"Lindstr\u00f6m","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023090107271589500_rkad055-B28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/acr.24560","article-title":"Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries","volume":"74","author":"Michelsen","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090107271589500_rkad055-B29","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2023090107271589500_rkad055-B30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acr.24523","article-title":"One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five Nordic biologic registries including more than 10,000 treatment courses","volume":"74","author":"Glintborg","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090107271589500_rkad055-B31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/annrheumdis-2022-eular.960","article-title":"Long-term persistence of first-line biologics for psoriatic arthritis and psoriasis: a cohort study of 23,423 patients from the French Health Insurance Database (SNDS). Abstract POS0075","volume":"81 (Suppl 1)","author":"Pina Vegas","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023090107271589500_rkad055-B32","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","article-title":"Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study","volume":"37","author":"Kiltz","year":"2020","journal-title":"Adv Ther"},{"key":"2023090107271589500_rkad055-B33","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40744-022-00460-x","article-title":"Interim 2-year analysis from SERENA: a real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab","volume":"9","author":"Kiltz","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2023090107271589500_rkad055-B34","first-page":"2262","article-title":"Outcome measures in psoriatic arthritis","volume":"32","author":"Gladman","year":"2005","journal-title":"J Rheumatol"},{"key":"2023090107271589500_rkad055-B35","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090107271589500_rkad055-B36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023090107271589500_rkad055-B37","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63(Suppl 11)","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090107271589500_rkad055-B38","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63 Suppl 11","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090107271589500_rkad055-B39","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3899\/jrheum.110279","article-title":"Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10","volume":"38","author":"Machado","year":"2011","journal-title":"J Rheumatol"},{"key":"2023090107271589500_rkad055-B40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s001130170111","article-title":"[Development and validation of the Visual Analogue Scale (VAS) Spine Score]","volume":"104","author":"Knop","year":"2001","journal-title":"Unfallchirurg"},{"key":"2023090107271589500_rkad055-B41","first-page":"889","article-title":"FRI0405 AQUILA study in Germany \u2013 real world data on secukinumab\u2019s effectiveness in psoriatic arthritis patients \u2013 results from an interim analysis","volume":"78(Suppl 2)","author":"Kiltz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023090107271589500_rkad055-B42","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"2023090107271589500_rkad055-B43","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"2023090107271589500_rkad055-B44","doi-asserted-by":"crossref","first-page":"815881","DOI":"10.3389\/fmed.2021.815881","article-title":"Association of gender, diagnosis, and obesity with retention rate of secukinumab in spondyloarthropathies: results from a multicenter real-world study","volume":"8","author":"Garc\u00eda-Dorta","year":"2021","journal-title":"Front Med"},{"key":"2023090107271589500_rkad055-B45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023090107271589500_rkad055-B46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis\u2014findings from a United Kingdom cohort","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023090107271589500_rkad055-B47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023090107271589500_rkad055-B48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2023090107271589500_rkad055-B49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkad055\/51201634\/rkad055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/3\/rkad055\/51321522\/rkad055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/3\/rkad055\/51321522\/rkad055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:27:48Z","timestamp":1693553268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkad055\/7246752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8,26]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkad055","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"rkad055"}}